MOTYS™  »  Preclinical  »  Clinical  »  Pipeline

Preclinical

In preclinical head-to-head comparisons,
MOTYS™ was proven superior to HA’s and steroids

Effect on pain and cartilage protection:
Potential for disease modification

In a rat OA model, MOTYS™ provided superior and more durable pain relief compared to HA or steroid.
MOTYS™ also provided superior effects on scores of cartilage protection.

Remarkably consistent, disease relevant biofactors

>300 regulatory proteins detected in MOTYS™ contribute to its biologic MoA

IL-1Ra
Anti-inflammatory

Reduction of pain and swelling

TIMP-3
Anti-catabolic

Mitigation of cartilage degeneration

bFGF
Pro-anabolic

New tissue formation through cell recruitment, differentiation, and/or proliferation

Contact Us

Our team can help to answer any of your questions.
Get in touch to learn more about Doron Therapeutics.